Soleus Capital Management L.P. Grows Stock Position in NeuroPace, Inc. (NASDAQ:NPCE)

Soleus Capital Management L.P. increased its holdings in NeuroPace, Inc. (NASDAQ:NPCEGet Rating) by 38.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,309,003 shares of the company’s stock after acquiring an additional 638,867 shares during the quarter. NeuroPace makes up about 2.3% of Soleus Capital Management L.P.’s investment portfolio, making the stock its 9th largest position. Soleus Capital Management L.P. owned approximately 9.50% of NeuroPace worth $23,275,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of America Corp DE acquired a new stake in NeuroPace in the 2nd quarter worth approximately $48,000. Wells Fargo & Company MN acquired a new position in NeuroPace during the second quarter worth about $243,000. Morgan Stanley purchased a new stake in shares of NeuroPace in the second quarter valued at approximately $181,000. American Century Companies Inc. boosted its stake in NeuroPace by 28.4% during the third quarter. American Century Companies Inc. now owns 517,192 shares of the company’s stock worth $8,198,000 after buying an additional 114,438 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in NeuroPace by 6.3% in the 3rd quarter. Geode Capital Management LLC now owns 117,960 shares of the company’s stock valued at $1,869,000 after buying an additional 6,980 shares in the last quarter. 77.56% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently issued reports on NPCE shares. SVB Leerink cut their price objective on shares of NeuroPace from $15.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, March 11th. Wells Fargo & Company reduced their price target on shares of NeuroPace from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Friday, March 11th. Zacks Investment Research raised NeuroPace from a “sell” rating to a “hold” rating in a research note on Wednesday, May 18th. Finally, Wolfe Research started coverage on NeuroPace in a research note on Tuesday, April 5th. They issued an “outperform” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $14.40.

Shares of NASDAQ NPCE opened at $6.19 on Friday. The stock has a market capitalization of $152.30 million and a PE ratio of -3.58. The stock has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $8.82. The company has a current ratio of 10.15, a quick ratio of 9.48 and a debt-to-equity ratio of 0.80. NeuroPace, Inc. has a twelve month low of $5.08 and a twelve month high of $25.75.

NeuroPace (NASDAQ:NPCEGet Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.11). The firm had revenue of $11.00 million for the quarter, compared to analyst estimates of $11.00 million. NeuroPace had a negative return on equity of 47.77% and a negative net margin of 85.42%. On average, equities analysts predict that NeuroPace, Inc. will post -1.93 earnings per share for the current year.

NeuroPace Company Profile (Get Rating)

NeuroPace, Inc operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely.

Recommended Stories

Want to see what other hedge funds are holding NPCE? Visit to get the latest 13F filings and insider trades for NeuroPace, Inc. (NASDAQ:NPCEGet Rating).

Institutional Ownership by Quarter for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with's FREE daily email newsletter.